The economic burden of depression among adults with rheumatoid arthritis in the United States.

Abstract:

AIMS:Depression is the most frequent comorbidity reported among patients with rheumatoid arthritis (RA). Comorbid depression negatively impacts RA patients' health-related quality-of-life, physical function, mental function, mortality, and experience of pain and symptom severity. The objective of this study was to assess healthcare utilization, expenditures, and work productivity among patients with RA with or without depression. MATERIALS AND METHODS:Data from adult patients who had at least two visits each related to RA and depression over a 1-year period were extracted from the Truven Health MarketScan research databases. Outcomes comprised healthcare resource utilization, work productivity loss, and direct healthcare costs comparing patients with RA with depression (n = 3,478) vs patients with RA without depression (n = 43,222). RESULTS:Patients with RA and depression had a significantly greater relative risk of hospitalization and number of all-cause and RA-related hospitalizations, utilization of emergency services, days spent in the hospital, physician visits, and RA-related surgeries compared with RA patients without depression. Patients with RA and depression had a higher risk of and experienced more events and days of short-term disability compared with patients without depression. The incremental adjusted annual all-cause and RA-related direct costs were $8,488 (95% CI = $6,793-$10,223) and $578 (95% CI = -$98-$1,243), respectively, when comparing patients with RA and depression vs RA only. LIMITATIONS:The current analysis is subject to the known limitations of retrospective studies based on administrative claims data. CONCLUSIONS:This study suggested increased healthcare utilization, work productivity loss, and economic burden among RA patients due to comorbid depression. These findings emphasize the importance of managing depression and including depression as a factor when devising treatment algorithms for patients with RA.

journal_name

J Med Econ

authors

Li N,Chan E,Peterson S

doi

10.1080/13696998.2019.1572015

subject

Has Abstract

pub_date

2019-04-01 00:00:00

pages

372-378

issue

4

eissn

1369-6998

issn

1941-837X

journal_volume

22

pub_type

杂志文章
  • Economic evaluation of sevelamer for the treatment of hyperphosphatemia in chronic kidney disease patients not on dialysis in the United Kingdom.

    abstract:OBJECTIVES:To determine the cost effectiveness of sevelamer vs calcium carbonate in patients with chronic kidney disease and not on dialysis (CKD-ND) from the perspective of the National Health Service (NHS) in the UK. METHODS:A Markov decision analytic model was developed to estimate (1) total life years (LYs), quali...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2013.792267

    authors: Thompson M,Bartko-Winters S,Bernard L,Fenton A,Hutchison C,Di Iorio B

    更新日期:2013-01-01 00:00:00

  • Adherence to dornase alfa treatment among commercially insured patients with cystic fibrosis.

    abstract:OBJECTIVE:To investigate adherence to dornase alfa therapy among commercially-insured patients with cystic fibrosis (CF) and to examine the impact of adherence on health and economic outcomes. METHODS:This retrospective cohort analysis included CF patients with ≥1 dornase alfa (Pulmozyme) pharmacy claim between 1 Octo...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2013.787427

    authors: Nasr SZ,Chou W,Villa KF,Chang E,Broder MS

    更新日期:2013-01-01 00:00:00

  • Budget impact analysis of the use of oral and intravenous anti-cancer drugs for the treatment of HER2-positive metastatic breast cancer.

    abstract:OBJECTIVES:Two anti-cancer drugs are currently approved for the treatment of HER2-positive metastatic breast cancer (MBC): trastuzumab-based therapy (TBT) administered intravenously as first line therapy until disease progression and lapatinib, an oral self-administered dual therapy with capecitabine (L+C) as second in...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2012.729549

    authors: Benjamin L,Buthion V,Iskedjian M,Farah B,Rioufol C,Vidal-Trécan G

    更新日期:2013-01-01 00:00:00

  • Healthcare costs among patients with chronic constipation: a retrospective claims analysis in a commercially insured population.

    abstract:OBJECTIVE:To evaluate total annual all-cause, gastrointestinal-related, and symptom-related healthcare costs among chronic constipation (CC) patients and estimate incremental all-cause healthcare costs of CC patients relative to matched controls. METHODS:Patients aged ≥18 years with continuous medical and pharmacy ben...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2013.860375

    authors: Cai Q,Buono JL,Spalding WM,Sarocco P,Tan H,Stephenson JJ,Carson RT,Doshi JA

    更新日期:2014-02-01 00:00:00

  • Assessing the economic impact of Rx-to-OTC switches: systematic review and guidelines for future development.

    abstract:INTRODUCTION:Switching drugs from prescription to non-prescription status (Rx-to-OTC) presents a unique set of challenges and opportunities to policy-makers and the industry in terms of managing health outcomes, pharmaceutical spending, and steering of consumer choices of therapy. Decision-analytic models are used to a...

    journal_title:Journal of medical economics

    pub_type: 杂志文章,评审

    doi:10.3111/13696998.2013.793693

    authors: Cohen J,Millier A,Karray S,Toumi M

    更新日期:2013-01-01 00:00:00

  • A long-term analysis evaluating the cost-effectiveness of biphasic insulin lispro mix 75/25 and mix 50/50 versus long-acting basal insulin analogs in the United States.

    abstract:OBJECTIVE:To evaluate the cost-effectiveness of biphasic insulin lispro mix 75/25 (LM75/25) and mix 50/50 (LM50/50) compared with a long-acting analog insulin (LAAI) regimen from the perspective of a US healthcare payer. METHODS:A published computer simulation model of diabetes was used to evaluate the cost-effectiven...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2012.675890

    authors: Pollock RF,Curtis BH,Valentine WJ

    更新日期:2012-01-01 00:00:00

  • Societal costs of multiple sclerosis in Ireland.

    abstract:AIMS:This paper evaluates the impact of multiple sclerosis (MS) in Ireland, and estimates the associated direct, indirect, and intangible costs to society based on a large nationally representative sample. MATERIALS AND METHODS:A questionnaire was developed to capture the demographics, disease characteristics, healthc...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2018.1427100

    authors: Carney P,O'Boyle D,Larkin A,McGuigan C,O'Rourke K

    更新日期:2018-05-01 00:00:00

  • Epidemiology, management, and economic impact of acute myeloid leukemia and myelodysplastic syndrome in Spain at the hospital level: a claims database analysis.

    abstract:OBJECTIVES:This study reviewed patient characteristics, management, and medical costs of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDSs) in Spanish hospitals. METHODS:Data were extracted from the Spanish Ministry of Health records via a claims database containing patient records from 192 private and ...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2020.1840180

    authors: Marsà A,Ascanio M,Diaz-García J,Darbà J

    更新日期:2020-11-02 00:00:00

  • Health-related quality-of-life in patients after elective surgery for abdominal aortic aneurysm.

    abstract:PURPOSE:The purpose of this study was to describe the health-related quality-of-life (QoL) in patients after elective surgery for abdominal aortic aneurysm (AAA) compared to a normal population and to study the association between QoL and number of years since surgery. METHODS:All Danish men who underwent elective sur...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2011.626822

    authors: Ehlers L,Laursen KB,Jensen MB

    更新日期:2011-01-01 00:00:00

  • Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events.

    abstract::Aims: Cumulative exogenous factor VIII (FVIII) exposure is an important predictor of developing neutralizing antibodies (inhibitors) to FVIII in patients with persons with hemophilia A (PwHA). The aim of this study was to model the costs of emicizumab versus FVIII prophylaxis and total treatment costs for patients wit...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2019.1669614

    authors: Patel AM,Corman SL,Chaplin S,Raimundo K,Sidonio RF

    更新日期:2019-12-01 00:00:00

  • Clinical and economic burden of chemotherapy-induced nausea and vomiting among patients with cancer in a hospital outpatient setting in the United States.

    abstract:OBJECTIVE:This study evaluated the overall burden of illness of chemotherapy-induced nausea and vomiting (CINV) and associated all-cause costs from a hospital's perspective (costs to the hospital) in patients with cancer treated with chemotherapy (CT) in the US hospital outpatient setting. METHODS:Patients with a canc...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2010.547237

    authors: Craver C,Gayle J,Balu S,Buchner D

    更新日期:2011-01-01 00:00:00

  • The association between use of mealtime insulin pens versus vials and healthcare charges and resource utilization in patients with type 2 diabetes: a retrospective cohort study.

    abstract:OBJECTIVE:To compare all-cause and diabetes-related resource utilization and healthcare charges among adults with type 2 diabetes mellitus who initiated therapy with mealtime insulin disposable pens or vials. METHODS:Data were obtained from the Innovus inVision database from January 1, 2006 through June 30, 2010. Gene...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2013.823091

    authors: Eby EL,Boye KS,Lage MJ

    更新日期:2013-10-01 00:00:00

  • The effects of global budget on cost control and readmission in rural China: a difference-in-difference analysis.

    abstract:BACKGROUND:Global budget (GB) is considered one of the most important payment methods available. Since a new round of healthcare system reforms in 2009, the Chinese government has been paying attention to this prospective payment. However, it is unclear whether GB has influenced cost control and how it works in rural C...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2017.1336448

    authors: He R,Miao Y,Ye T,Zhang Y,Tang W,Li Z,Zhang L

    更新日期:2017-09-01 00:00:00

  • Budget impact analysis of secukinumab versus adalimumab in the treatment of ankylosing spondylitis.

    abstract:BACKGROUND:Biologic treatments have enhanced the treatment outcomes of patients with active ankylosing spondylitis (AS). Until recently, TNF-alpha-inhibitors have been the only biologics approved for the treatment of active AS. The objective of this study was to assess the potential financial impact of the first non-TN...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2018.1551227

    authors: Purmonen T,Törmälehto S,Wahlman H,Puolakka K

    更新日期:2019-02-01 00:00:00

  • Reduction in hospital costs and resource consumption associated with the use of advanced topical hemostats during inpatient procedures.

    abstract:OBJECTIVE:The use of hemostatic agents has increased over time for all surgical procedures. The purpose of this study was to evaluate the newer topical absorbable hemostat products Surgicel * Fibrillar † and Surgicel SNoW ‡ (Surgicel advanced products, abbreviated as SAPs) compared to the older product Surgicel Origina...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2015.1017503

    authors: Martyn D,Kocharian R,Lim S,Meckley LM,Miyasato G,Prifti K,Rao Y,Riebman JB,Scaife JG,Soneji Y,Corral M

    更新日期:2015-06-01 00:00:00

  • Budget impact of ferric carboxymaltose treatment in patients with chronic heart failure and iron deficiency in Spain.

    abstract:OBJECTIVE:The treatment of iron deficiency (ID) with ferric carboxymaltose (FCM) improves the functional class and quality of life of chronic heart failure (CHF) patients with reduced left ventricular ejection fraction (LVEF), and reduces the rate of hospitalization due to worsening CHF. This study aims to evaluate the...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2020.1838872

    authors: Delgado JF,Oliva J,González-Franco Á,Cepeda JM,García-García JÁ,González-Domínguez A,Garcia-Casanovas A,Jiménez Merino S,Comín-Colet J

    更新日期:2020-10-30 00:00:00

  • Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data.

    abstract:OBJECTIVE:Compare long-term costs and outcomes of lurasidone to aripiprazole among adults with schizophrenia in the US who previously failed ≥1 atypical antipsychotic (olanzapine, risperidone, quetiapine, or ziprasidone) based on an indirect comparison of outcomes data from clinical trials. METHODS:A 5-year Markov coh...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2013.807813

    authors: Rajagopalan K,Hassan M,O'Day K,Meyer K,Grossman F

    更新日期:2013-07-01 00:00:00

  • Economic burden, work, and school productivity in individuals with tuberous sclerosis and their families.

    abstract:AIMS:Tuberous sclerosis complex (TSC) is a multi-organ autosomal-dominant, genetic disorder with incomplete penetrance. The multiple manifestations of TSC and impacts to numerous organ systems represent significant disease, healthcare, and treatment burden. The economic and employment burden of the disease on individua...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2018.1487447

    authors: Skalicky AM,Rentz AM,Liu Z,Said Q,Nakagawa JA,Frost MD,Wheless JW,Dunn DW

    更新日期:2018-10-01 00:00:00

  • A Canadian cost-effectiveness analysis of transcatheter mitral valve repair with the MitraClip system in high surgical risk patients with significant mitral regurgitation.

    abstract:OBJECTIVE:In patients with significant mitral regurgitation (MR) at high risk of mortality and morbidity from mitral valve surgery, transcatheter mitral valve repair with the MitraClip System is associated with a reduction in MR and improved quality-of-life and functional status compared with baseline. The objective wa...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2014.923892

    authors: Cameron HL,Bernard LM,Garmo VS,Hernandez JB,Asgar AW

    更新日期:2014-08-01 00:00:00

  • Comparison of treatment costs in inadequately controlled type 2 diabetes in Germany based on the APOLLO trial with insulin glargine.

    abstract:OBJECTIVE:A cost analysis of once-daily insulin glargine versus three-times daily insulin lispro in combination with oral antidiabetic drugs (OADs) for insulin-naive type 2 diabetes patients in Germany based on the APOLLO trial (A Parallel design comparing an Oral antidiabetic drug combination therapy with either Lantu...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696990902949614

    authors: Bretzel RG,Dippel FW,Linn T,Neilson AR

    更新日期:2009-06-01 00:00:00

  • Estimating the economic benefits of positive shifts in fibromyalgia severity: an exploratory analysis based on modeling of clinical trial data of pregabalin.

    abstract:OBJECTIVE:To estimate the annualized differences in direct medical and indirect costs associated with improvement in fibromyalgia (FM) severity among pregabalin-treated patients. METHODS:Data from three clinical trials of pregabalin in patients with FM were modeled; efficacy results were extrapolated. Mean annual cost...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2012.727930

    authors: Cappelleri JC,Bushmakin AG,Zlateva G,Chandran A

    更新日期:2013-01-01 00:00:00

  • Cost, healthcare resource utilization, and adherence of individuals with diabetes using U-500 or U-100 insulin: a retrospective database analysis.

    abstract:OBJECTIVE:To describe costs, healthcare resource utilization, and adherence of US patients receiving human regular U-500 insulin (U-500R), compared to patients receiving high-dose (>200 units/day) U-100 insulins (U-100) by subcutaneous injection for the treatment of diabetes. METHODS:A retrospective analysis of data f...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2013.772059

    authors: Eby EL,Wang P,Curtis BH,Xie J,Haldane DC,Idris I,Peters AL,Hood RC,Jackson JA

    更新日期:2013-01-01 00:00:00

  • Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis.

    abstract:OBJECTIVE:This study compared real-world treatment patterns and healthcare costs among biologic-naive psoriasis patients initiating apremilast or biologics. METHODS:A retrospective cohort study was conducted using the Optum Clinformatics™ claims database. Patients with psoriasis were selected if they had initiated apr...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2019.1571500

    authors: Wu JJ,Pelletier C,Ung B,Tian M

    更新日期:2019-04-01 00:00:00

  • Healthcare costs of pregnancy in systemic lupus erythematosus: retrospective observational analysis from a US health claims database.

    abstract:OBJECTIVE:Systemic lupus erythematosus is a complex autoimmune disease, most frequently affecting women of childbearing age. Women with lupus are at increased risk of pregnancy complications that are exacerbated by active disease. Despite this, their use of medications and hospital resources has not been extensively st...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2015.1066796

    authors: Petri M,Daly RP,Pushparajah DS

    更新日期:2015-01-01 00:00:00

  • Evaluating the cost-effectiveness of secukinumab in moderate-to-severe psoriasis: a Japanese perspective.

    abstract:AIM:To evaluate the cost-effectiveness of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, compared to other clinically used biologics (adalimumab, infliximab, and ustekinumab) in Japan for the treatment of moderate-to-severe psoriasis from the healthcare system (total costs) and patient co-payment ...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2018.1532905

    authors: Igarashi A,Igarashi A,Graham CN,Gilloteau I,Tani Y

    更新日期:2018-10-26 00:00:00

  • The cost-effectiveness of a new percutaneous ventricular assist device for high-risk PCI patients: mid-stage evaluation from the European perspective.

    abstract:OBJECTIVE:A new and smaller percutaneous ventricular assist device (pVAD, Impella, Abiomed, Danvers, MA) has been developed to provide circulatory support in hemodynamically unstable patients and to prevent hemodynamic collapse during high-risk percutaneous coronary interventions (PCI). The objective of the study was t...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2012.762004

    authors: Roos JB,Doshi SN,Konorza T,Palacios I,Schreiber T,Borisenko OV,Henriques JP

    更新日期:2013-01-01 00:00:00

  • A systematic review of pharmacoeconomic guidelines.

    abstract:OBJECTIVE:To review, summarize, and analyze both similarities and differences of pharmacoeconomic (PE) guidelines, to enable researchers to access their characteristics and the current state of PE guidelines; furthermore, to learn which methodological issues still remain contested and to promote the methodological deve...

    journal_title:Journal of medical economics

    pub_type: 杂志文章,评审

    doi:10.1080/13696998.2017.1387118

    authors: Zhao Y,Feng HM,Qu J,Luo X,Ma WJ,Tian JH

    更新日期:2018-01-01 00:00:00

  • A cost-effectiveness analysis comparing the originator follitropin alfa to its biosimilars in patients undergoing a medically assisted reproduction program from a French perspective.

    abstract:OBJECTIVE:To assess the cost-effectiveness (CE) of the originator follitropin-α (Gonal-F) in patients undergoing a medically assisted reproduction (MAR) program in comparison to its biosimilars Bemfola and Ovaleap in a French context. METHODS:A CE model was developed for France with a National Health Service (NHS) per...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2018.1551226

    authors: Grynberg M,Murphy C,Doré C,Fresneau L,Paillet S,Petrica N,Frédérique M,Ravonimbola H

    更新日期:2018-11-21 00:00:00

  • A UK analysis of the cost of switching renal transplant patients from an immediate-release to a prolonged-release formulation of tacrolimus based on differences in trough concentration variability.

    abstract:BACKGROUND AND AIMS:Randomized controlled trials have shown that a once-daily prolonged-release (PR) tacrolimus formulation (PR tacrolimus; Advagraf * ), is non-inferior to a twice-daily immediate-release (IR) tacrolimus formulation (IR tacrolimus; Prograf † ) in terms of biopsy-proven acute rejection, graft failure an...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2014.916713

    authors: Muduma G,Odeyemi I,Pollock RF

    更新日期:2014-07-01 00:00:00

  • Predictors for total hospital and cardiology cost claims among patients with atrial fibrillation initiating dabigatran or acenocoumarol in The Netherlands.

    abstract:AIMS:The prevalence of atrial fibrillation (AF) has increased over the past years due to aging of the population, and healthcare costs associated with AF reflect a significant financial burden. The aim of this study was to explore predictors for the real-world AF-related in-hospital costs in patients that recently init...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2017.1363766

    authors: Jacobs MS,van Leent MWJ,Tieleman RG,Jansman FGA,Cao Q,Postma MJ,van Hulst M

    更新日期:2017-12-01 00:00:00